As of December 31, 2025, Beam held nearly $1.25 billion in cash and marketable securities, which management expects will finance ongoing operations, support BEAM-302 development, and fund the anticipated launch of its risto-cel therapy through 2029. H.C. Wainwright maintained a Buy rating and set an $80 price target on Beam Therapeutics, implying approximately 197% upside potential based on its clinical progress and regulatory advancements. ARK Invest purchased 218,529 shares of Beam Therapeutics valued at roughly $5.9 million on February 13, following a 3.7% share gain, signaling growing institutional confidence in the company’s pipeline and strategic direction. Beam Therapeutics reached an agreement with the U.S. FDA to leverage alpha-1 antitrypsin biomarker data over a 12-month period as the primary basis for its BEAM-302 Biologics License Application, accelerating the approval process for its alpha-1 antitrypsin deficiency therapy.